These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 1319214)

  • 1. Differences in the repertoires of basement membrane degrading enzymes in two carcinoma sublines with distinct patterns of site-selective metastasis.
    Brodt P; Reich R; Moroz LA; Chambers AF
    Biochim Biophys Acta; 1992 Jun; 1139(1-2):77-83. PubMed ID: 1319214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of carcinoma cell invasion and liver metastases formation by the cysteine proteinase inhibitor E-64.
    Navab R; Mort JS; Brodt P
    Clin Exp Metastasis; 1997 Mar; 15(2):121-9. PubMed ID: 9062388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells.
    Reich R; Thompson EW; Iwamoto Y; Martin GR; Deason JR; Fuller GC; Miskin R
    Cancer Res; 1988 Jun; 48(12):3307-12. PubMed ID: 2836052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Invasive human fibrosarcoma DNA mediated induction of a 92 kDa gelatinase/type IV collagenase leads to an invasive phenotype.
    Kubota S; Mitsudomi T; Yamada Y
    Biochem Biophys Res Commun; 1991 Dec; 181(3):1539-47. PubMed ID: 1662501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retinoic acid inhibition of human melanoma cell invasion through a reconstituted basement membrane and its relation to decreases in the expression of proteolytic enzymes and motility factor receptor.
    Hendrix MJ; Wood WR; Seftor EA; Lotan D; Nakajima M; Misiorowski RL; Seftor RE; Stetler-Stevenson WG; Bevacqua SJ; Liotta LA
    Cancer Res; 1990 Jul; 50(13):4121-30. PubMed ID: 2162253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in expression of metalloproteinases and plasminogen activators in murine melanocytes and B16 melanoma variants: lack of association with in vitro invasion.
    Huijzer JC; Uhlenkott CE; Meadows GG
    Int J Cancer; 1995 Sep; 63(1):92-9. PubMed ID: 7558459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of multiple matrix metalloproteinases and urokinase type plasminogen activator in cultured Kaposi sarcoma cells.
    Meade-Tollin LC; Way D; Witte MH
    Acta Histochem; 1999 Jul; 101(3):305-16. PubMed ID: 10443293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of proteolytic enzymes in the in vitro amnion model for basement membrane invasion.
    Persky B; Ostrowski LE; Pagast P; Ahsan A; Schultz RM
    Cancer Res; 1986 Aug; 46(8):4129-34. PubMed ID: 3524801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human prostate tumor angiogenesis in nude mice: metalloprotease and plasminogen activator activities during tumor growth and neovascularization of subcutaneously injected matrigel impregnated with human prostate tumor cells.
    Wilson MJ; Sinha AA
    Anat Rec; 1997 Sep; 249(1):63-73. PubMed ID: 9294650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Granulocyte, granulocyte-macrophage, and macrophage colony-stimulating factors can stimulate the invasive capacity of human lung cancer cells.
    Pei XH; Nakanishi Y; Takayama K; Bai F; Hara N
    Br J Cancer; 1999 Jan; 79(1):40-6. PubMed ID: 10408691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective inhibition of proteolytic enzymes in an in vivo mouse model for experimental metastasis.
    Ostrowski LE; Ahsan A; Suthar BP; Pagast P; Bain DL; Wong C; Patel A; Schultz RM
    Cancer Res; 1986 Aug; 46(8):4121-8. PubMed ID: 3089587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.
    Mazzieri R; Masiero L; Zanetta L; Monea S; Onisto M; Garbisa S; Mignatti P
    EMBO J; 1997 May; 16(9):2319-32. PubMed ID: 9171346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model.
    Kobayashi H; Gotoh J; Shinohara H; Moniwa N; Terao T
    Thromb Haemost; 1994 Apr; 71(4):474-80. PubMed ID: 8052966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mouse trophoblastic cell lines: II--Relationship between invasive potential and proteases.
    Sharma RK
    In Vivo; 1998; 12(2):209-17. PubMed ID: 9627804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of type IV collagenase and plasminogen activator in a hamster fibrosarcoma by basement membrane components and lung fibroblasts.
    Teale DM; Khidair IA; Potter CW; Rees RC
    Br J Cancer; 1988 May; 57(5):475-80. PubMed ID: 2840108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Constitutive expression and secretion of proteases in non-metastatic SP1 mammary carcinoma cells and its metastatic sublines.
    Korczak B; Kerbel RS; Dennis J
    Int J Cancer; 1991 Jun; 48(4):557-61. PubMed ID: 2045200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of collagenase IV (basement membrane collagenase) activity in murine tumor cell hybrids that differ in metastatic potential.
    Turpeenniemi-Hujanen T; Thorgeirsson UP; Hart IR; Grant SS; Liotta LA
    J Natl Cancer Inst; 1985 Jul; 75(1):99-103. PubMed ID: 2989606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth-factor-independence and invasive properties of colorectal carcinoma cells.
    Williams NN; Györfi T; Iliopoulos D; Herlyn D; Greenstein D; Linnenbach AJ; Daly JM; Jensen P; Rodeck U; Herlyn M
    Int J Cancer; 1992 Jan; 50(2):274-80. PubMed ID: 1730521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of the Mr 72,000 type IV collagenase by the type I insulin-like growth factor receptor.
    Long L; Navab R; Brodt P
    Cancer Res; 1998 Aug; 58(15):3243-7. PubMed ID: 9699649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory effect of amiloride on the urokinase plasminogen activators in prostatic cancer.
    Ray P; Bhatti R; Gadarowski J; Bell N; Nasruddin S
    Tumour Biol; 1998; 19(1):60-4. PubMed ID: 9422083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.